{"ticker": {"uuid": "544e4181-8e3d-4e4d-90cc-e108cd37a5dc", "symbol": "KLRS", "name": "Kalaris Therapeutics, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOS3k3T0xVbmRhUVMzWXVZYi1EZFlTeVVoV1R6WDVjcG83ZFZnUHRad3htZVpKUmNCVVVqaG4zV01ZUE5TbmVDZ2RyNHFZOEF0OUhUU0xTSmsySVB2RDJTQWNJZ1hNVUE2UkozR0NxVzNCbVl4WTFwZzRteHFFU2RmSjJORVA5OUhBS3VfdFdUU2ZOMmZFU0RPWUMxOHA1VnJLRFdMVQ?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:58+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kalaris Therapeutics (KLRS) Edges Higher as Stock Tests Key Resistance Near $5.12 - Wave Extension", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPNm1mNml1Wm5zQnVic3pMcnNWVjdjUmV3VzlnN1U0MTZIeGlUTDhBSlo1d0FYQkdJd1NKRThFZWQ2TVB2T1BxNnpQc1lGWDlBUjBiU2Y2RGVGa0hpd0tYcmw2VHkxZGp2bkRfUDRIQUluTk1hWkNUcVZ4SzVOWkliMlgzVDJ3cmI0VGRuMlhQbXlDNk1Pa1c5QjM2Yk5YTXd6YV9vdkhJZzRzWHNaMnRzQ1IyMTFVZlM4OWZR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-08T13:43:25+00:00", "published_display": "08 Jul 2026 13:43", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics appoints Laurie Keating to board By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPR2J0LU5pYXMxTFVxbVQ4c0ZJOHRTM0dpamxCa0lSQXRuTWxPTlpVX1VDTThhUU5OOTJnT0EwMmdxQnBhblFjb1N6SUx6b0w3OXNWRTdUSm1KaFJRTjdYUkJjY2NfSzZEOXkxUE9oazFoLUM2aGJNc2t2MG5xZUt5UWdtenRKUUVnaFZmWURUVU4xV2Rza3NPc3hvQVE4bHB1YWFhQURfSy1LM0RFWXVXM3M1Yms?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-06T21:15:25+00:00", "published_display": "06 Jul 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics Announces Board and Audit Committee Changes", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNRzBidW1SakxXQXVBTFhhVEI1US1qd0t5WE9vZHNkZmJqTEhzQWFfbDJMaHR1eFdjQTE3YmNzYnJVM2J0T3pXV3dyWWNhZDV5TVhQSzNBSVA2TFlmRUsxUHRWbmVkNHY3cVFYSWFKc244dDU3bmdhcW80eXkzSnJnNXVpVDFWSW9wQnZfb3pIcVlKQl9TSTUtak5CeENEX0U3TW8zS3A4dUNCWjJuZ0x5WXlZVUdLRUU?oc=5", "source_name": "TipRanks", "published_at": "2026-07-06T20:35:52+00:00", "published_display": "06 Jul 2026 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Appoints Laurie Keating to Board of Directors", "summary": "Kalaris Therapeutics has announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. Keating, a highly experienced biotechnology executive, will bring extensive strategic, operational, and legal expertise to the board, aiding Kalaris in its ne", "url": "https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/kalaris-appoints-laurie-keating-to-board-of-directors/2379340", "source_name": "The Manila Times", "published_at": "2026-07-06T20:40:08", "published_display": "06 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Kalaris Appoints Laurie Keating to Board of Directors", "summary": "The provided content is a placeholder document. Without access to the actual content, a summary cannot be generated. It is expected to be a press release announcing the appointment of Laurie Keating to the Board of Directors of Kalaris.", "url": "https://www.moomoo.com/news/post/72538507/press-release-kalaris-appoints-laurie-keating-to-board-of-directors?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-06T19:43:10", "published_display": "06 Jul 2026 19:43", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Kalaris Therapeutics, Inc. \u2013 NASDAQ:KLRS", "summary": "The article displays the \"Price to book forward\" for Kalaris Therapeutics, Inc. (NASDAQ: KLRS) on TradingView. It provides basic information about the company including its stock market listing and offers links to various financial data, news, and community features on the platfo", "url": "https://www.tradingview.com/symbols/NASDAQ-KLRS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:09:25", "published_display": "30 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Kalaris Therapeutics, Inc. \u2013 NASDAQ:KLRS", "summary": "This article mentions the enterprise value to EBITDA forward for Kalaris Therapeutics, Inc., traded on NASDAQ under the symbol KLRS. It appears to be a stub or a section from a financial data platform, providing a heading for a specific financial metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-KLRS/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T11:41:36", "published_display": "29 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling", "summary": "Kalaris Therapeutics, Inc. announced the upcoming presentation of Phase 1a clinical data for TH103 at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. The presentation will detail the first-in-human evaluation of TH103, a dual-targeting VEGF/HSPG biologic fo", "url": "https://www.manilatimes.net/2026/06/23/tmt-newswire/globenewswire/kalaris-announces-upcoming-presentation-of-th103-phase-1a-clinical-data-at-american-society-of-retina-specialists-ph-1b2-clinical-trial-actively-enrolling/2370862", "source_name": "The Manila Times", "published_at": "2026-06-26T17:10:34", "published_display": "26 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics, Inc. Actuals & Estimates (NASDAQ:KLRS)", "summary": "This article provides an overview of Kalaris Therapeutics, Inc. (NASDAQ:KLRS) stock performance, financial data, and analyst forecasts. It details the current stock price, historical highs and lows, market capitalization, earnings per share, and revenue, alongside analyst price t", "url": "https://www.tradingview.com/symbols/NASDAQ-KLRS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:10:10", "published_display": "26 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KLRS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast and analysis for Kalaris Therapeutics, Inc. (KLRS) stock, including analyst price targets, historical stock performance, and financial data. It covers current stock price, volatility, market capitalization, and upcoming earnings reports, ", "url": "https://www.tradingview.com/symbols/NASDAQ-KLRS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:40:11", "published_display": "25 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris to present Phase 1a data on retinal drug at ASRS meeting By Investing.com", "summary": "Kalaris Therapeutics (NASDAQ:KLRS) announced it will present Phase 1a data for its investigational drug TH103, a dual-targeting biologic for neovascular age-related macular degeneration, at the American Society of Retina Specialists 2026 Annual Meeting. The company also stated th", "url": "https://m.in.investing.com/news/stock-market-news/kalaris-to-present-phase-1a-data-on-retinal-drug-at-asrs-meeting-93CH-5466613?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-06-24T01:10:18", "published_display": "24 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris to present Phase 1a data on retinal drug at ASRS meeting", "summary": "Kalaris Therapeutics (NASDAQ:KLRS) announced it will present Phase 1a data for its investigational drug TH103, a dual-targeting biologic for neovascular age-related macular degeneration, at the American Society of Retina Specialists 2026 Annual Meeting on July 17, 2026. The compa", "url": "https://ng.investing.com/news/stock-market-news/kalaris-to-present-phase-1a-data-on-retinal-drug-at-asrs-meeting-93CH-2570104", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T23:10:27", "published_display": "23 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics (Nasdaq:KLRS) - Stock Analysis", "summary": "Kalaris Therapeutics (KLRS) is a clinical-stage biopharmaceutical company focused on treatments for retinal diseases. The company is currently unprofitable and has seen dilution of shares, but its lead asset, TH103, has shown positive Phase 1a data for neovascular Age-Related Mac", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-klrs/kalaris-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-21T23:40:11", "published_display": "21 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics Inc (KLRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Kalaris Therapeutics Inc (KLRS), focusing on business segments, regional revenue, and profit contribution. It notes that relevant data for these categories for FY2019, FY2020, and FY2021 have not yet been disclosed by the company. The", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-klrs/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T15:09:53", "published_display": "19 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics Inc (KLRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Kalaris Therapeutics Inc (KLRS), detailing its price momentum, support and resistance levels, and insights from various technical indicators and moving averages. The stock currently trades between a resistance of $5.54 and support of ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-klrs/technical", "source_name": "TradingKey", "published_at": "2026-06-18T21:09:47", "published_display": "18 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics Inc (KLRS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Kalaris Therapeutics Inc (KLRS). It indicates that the company has not distributed any dividends in the past five years but has a significant 23-to-1 merger-related stock split scheduled for January 10, 202", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-klrs/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:01", "published_display": "18 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics Inc (KLRS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Kalaris Therapeutics Inc (KLRS) has an earnings forecast score of 8.75, ranking high in the Biotechnology & Medical Research industry. Analysts have set an average price target of $20.00, with varying highs and lows, and largely recommend a \"Buy\" for the stock. The company's prev", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-klrs/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:01", "published_display": "17 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics Climbs 7.8% as Biotech Momentum Builds (KLRS) - Wave Extension", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPM1p2am05cHhSV1kycV9GeXFHN2JVRDdlUWhxUG1iT19Xbjcxcm80aFAyelE5RWkwYlFjNm1pVEExWk1ZcVJBb2ZDTkRGaVVfOGZPaTRabHhaUmJZR090azZNR1pEVnNpZnFHcXNvSWE0dHA1bWhYWTJ0aWZiQnJVbU1VZFloZW1sbnhSbDdIemFRRlNKeWpWLTI5N1hDaVc0QTVzZE15UQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris to Present at Clinical Trials at the Summit 2026", "summary": "Kalaris Therapeutics, Inc. announced it will present Phase 1a clinical data for its lead asset, TH103, at Clinical Trials at the Summit (CTS) 2026. The presentation will feature single ascending dose results from treatment-na\u00efve patients with Neovascular Age-Related Macular Degen", "url": "https://www.manilatimes.net/2026/06/12/tmt-newswire/globenewswire/kalaris-to-present-at-clinical-trials-at-the-summit-2026/2364390", "source_name": "The Manila Times", "published_at": "2026-06-17T02:09:25", "published_display": "17 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen initiates Kalaris stock coverage with buy rating", "summary": "TD Cowen initiated coverage on Kalaris Therapeutics Inc. (NASDAQ:KLRS) with a buy rating, highlighting its differentiated anti-VEGF treatment TH103 and a potential $15 billion market opportunity. Analysts have set price targets ranging from $7 to $25. Despite a previous trial pau", "url": "https://m.uk.investing.com/news/stock-market-news/td-cowen-initiates-kalaris-stock-coverage-with-buy-rating-93CH-4727617?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-15T19:40:45", "published_display": "15 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KLRS Initiates Coverage On by TD Cowen -- Rating Set to Buy", "summary": "TD Cowen has initiated coverage on Kalaris Therapeutics (KLRS) with a Buy rating, noting the company's focus on developing therapeutics for retinal diseases. Despite a low GF Score\u2122 of 14/100 indicating potential profitability challenges, the company has a strong financial streng", "url": "https://www.gurufocus.com/news/8916771/klrs-initiates-coverage-on-by-td-cowen-rating-set-to-buy", "source_name": "GuruFocus", "published_at": "2026-06-15T18:37:40", "published_display": "15 Jun 2026 18:37", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Initiates Kalaris Therapeutics at Buy", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/td-cowen-initiates-kalaris-therapeutics-100528337.html", "source_name": "MT Newswires", "published_at": "2026-06-15T10:05:28+00:00", "published_display": "15 Jun 2026 10:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First-in-human TH103 eye trial data to be presented at Las Vegas summit", "summary": "Kalaris Therapeutics (Nasdaq: KLRS) will present Phase 1a clinical data for its lead asset, TH103, at Clinical Trials at the Summit (CTS) 2026 in Las Vegas. The presentation will detail single ascending dose results from treatment-na\u00efve patients with neovascular age-related macul", "url": "https://www.stocktitan.net/news/KLRS/kalaris-to-present-at-clinical-trials-at-the-summit-087ko6zxj3zq.html", "source_name": "Stock Titan", "published_at": "2026-06-13T07:10:08", "published_display": "13 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KLRS SEC Filings - Kalaris Therapeutics Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for investors to access Kalaris Therapeutics Inc. (KLRS) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, and 8-K material event disclosures. Recent filings cover the re-election of directors, ratification of auditor", "url": "https://www.stocktitan.net/sec-filings/KLRS/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:10:19", "published_display": "12 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOSnJXLW05bjhaNFNtZTExWmptRkktcGxIblZVenpyekpQYXo5Rm9mdlNYNjZScUZ3ZjBYNmFDY2tzMXVrUnlIVU1EcEpFY04zSGNuNU9tQlVvTDNNaDdHMHhzYjRNMFpFRENPeXVaUEZuTDkzNFRsVU9QWWpPalZZRFNiM2MwY2FMV25TUHRoUDFfa3BqajlibVl0a1NLWGJINHpN?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics (KLRS) director receives 9,000-stock option grant", "summary": "Kalaris Therapeutics director Srinivas Akkaraju was granted options to buy 9,000 shares of common stock on June 3, 2026, with an exercise price of $4.72 per share. These options will vest in full on the earlier of June 3, 2027, or the company\u2019s 2027 Annual Meeting of Stockholders", "url": "https://www.stocktitan.net/sec-filings/KLRS/form-4-kalaris-therapeutics-inc-insider-trading-activity-e1a07873e8aa.html", "source_name": "Stock Titan", "published_at": "2026-06-05T04:09:54", "published_display": "05 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics (KLRS) director awarded 9,000 stock options", "summary": "Kalaris Therapeutics director Anthony P. Adamis has been granted 9,000 stock options with an exercise price of $4.72 per share and an expiration date of June 2, 2036. These options are scheduled to vest fully by June 3, 2027, or the company's 2027 annual meeting, contingent on hi", "url": "https://www.stocktitan.net/sec-filings/KLRS/form-4-kalaris-therapeutics-inc-insider-trading-activity-da746940ddc6.html", "source_name": "Stock Titan", "published_at": "2026-06-05T03:38:47", "published_display": "05 Jun 2026 03:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics (KLRS) holders elect board, choose annual say-on-pay", "summary": "Kalaris Therapeutics, Inc. (KLRS) announced the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. Shareholders elected three directors, Napoleone Ferrara, David Hallal, and Leone Patterson, with strong support. Furthermore, they approved the advisory vote o", "url": "https://www.stocktitan.net/sec-filings/KLRS/8-k-kalaris-therapeutics-inc-reports-material-event-3bd83e236c1e.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:08:56", "published_display": "04 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Kalaris Therapeutics, Inc. Insider Trading Activity", "summary": "Kalaris Therapeutics, Inc. director Michael Dybbs was granted 9,000 stock options, with an exercise price of $4.72 per share and an expiration date of June 2, 2036. These options are scheduled to vest fully by June 3, 2027, or the date of the company's 2027 Annual Meeting of Stoc", "url": "https://www.stocktitan.net/sec-filings/KLRS/form-4-kalaris-therapeutics-inc-insider-trading-activity-3efdd24553f3.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:08:56", "published_display": "04 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics (KLRS) director receives stock options for 9,000 shares", "summary": "Kalaris Therapeutics director David Hallal was granted stock options for 9,000 shares of common stock with an exercise price of $4.72 per share. The options, granted on June 3, 2026, vest in full on the earlier of June 3, 2027, or the company's 2027 annual stockholder meeting, co", "url": "https://www.stocktitan.net/sec-filings/KLRS/form-4-kalaris-therapeutics-inc-insider-trading-activity-f85d3e3ed18a.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:08:56", "published_display": "04 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kaskela Law LLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. Shareholders and Encourages Investors With Losses to Contact The Firm - KLRS", "summary": "Kaskela Law LLC has initiated an investigation into potential legal claims for shareholders of Kalaris Therapeutics, Inc. (NASDAQ:KLRS). This follows a significant decline in Kalaris' stock price, dropping nearly 45% to under $5.00 per share since its merger with AlloVir, Inc. in", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/kaskela-law-llc-announces-investigation-on-behalf-of-kalaris-the-1173256", "source_name": "ACCESS Newswire", "published_at": "2026-06-04T07:59:00", "published_display": "04 Jun 2026 07:59", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock Higher - Estimate Revision Count", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQRnVSaGxtYzljQmFQclRVU3NZeTYxRGhUOVp1RkU5ekdxN0dndlNjS0lrd2toTlBJZWNYQV9WdGFyeUNvc0h4ZmRfTkpwQ3VwVDVjS2hvWjZpZHk5UDIwOHMwaEZkLXoyczUtUnVFb3U1LW84QWxrTjVoX24weWZQU0Nmdmp2SzFrNHcxYVRLT09xemV2MHlqSzhxdlJ4UXJRdHk3d2Rsb1hPM1N3c2s0VnRSSDkteUhkSU5oc2F0RlFaUU9pMXktNG93?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre-Revenue Biotech - Quarterly Profit Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPc093dmtGV2lXb0JIS0RKSzNqY0hXZXFYSHZSdVFGM3RHRjZMY3QyYnZhSjh2UFpkUktyR0wtY1J6TTV3a1otWnBEOWhhd3hpSUNlQ09UenBtMGx3bktYTGVXM05fU3dtbTVyaHpnaWU4OWxpeVNreFBtTHlEaVVHVHR4VlJiTjE1TzQ2SnZieGVCMU5zNnlXX1A1WXZPdUlKNXk0czlDZ3pxSkg0SWJSdS03UURxMTN5S2dUems2UWdram80Y09tTG5jT0l5TGdQSjlKT25LMzNQclhxc2UwbmJYTUFhUQ?oc=5", "source_name": "M\u011bsto B\u0159eclav", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics director Akkaraju\u2019s fund buys $1.18m stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOUDdqM21RYml1MkNmZEp5Rl8wWVl6NUZ0MEJHdkQtQWl1T3ViLWVBNlExbkNNbmdDdWJhejROTC1ULTdxWXVDemRxUm5UZGNpUVI5MmU3RURuVi1CcmpaOGhJUzY5RXc5VGRtUFNsV1BucFc5alg2cXRlQ2tha2I5S0l0RFFaNG9BSi1mUjhYaElJYmVERFk1bzl0bzZaVlhvMzlFT1A4THN4N3BqN0VURWJacEpGSFNsVmFrZGVLZ011bWc?oc=5", "source_name": "Investing.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wedbush Initiates Kalaris Therapeutics at Outperform With $17 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-initiates-kalaris-therapeutics-outperform-114847081.html", "source_name": "MT Newswires", "published_at": "2026-05-14T11:48:47+00:00", "published_display": "14 May 2026 11:48", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kalaris-reports-first-quarter-2026-120000027.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T12:00:00+00:00", "published_display": "12 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kalaris Therapeutics (NASDAQ:KLRS) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxOVEZUVnZWZFhtbmJLYTRoX3NidzhyWjlOcERKYlFwM1lsMjVmWHJSS3BXUEVVNVVpNTM1TEhrMmR3Zi1DYlFxeEFlVjd4R2tpMGZ2QjEteWZlWWJSVTBZaW1kaHgwc04yQVgtR0pmUmc2czNoVGRTY0JqSWRSc1hrRUlnM2dsZHdwTkpMNjZIMWZtRUhnTGJzNTFyYTBzQ19JUkJUVDBKeDJ5RGhZQVV1eXBOV2lqOGxGdXZ5NHhvR1p0cDVTT3BLVHJ1WE5ubU9mNUh0a3dCaUFzaF9sTjdYUDRWSG1RdWdLLWfSAe8BQVVfeXFMUGE5cXlGNmdaMkFIOUZqNFBQVWx5MTZPT0tDbWRXM0N2M3NBTENGSnNtVnVDTWg0cG11Smp5eHVwbTcwRDFDR0tmY0h6aG1OVDVRRW45RXZCaHRJX3Q5V0xtQ01nbWdjdDlDSDlMZjE5R09ZRlVvV3NEeUtwRVd1NW8wZmVic2NHUDlEakswajdxd0FpN0xiYUgxYkt6VjV6UWpJMkVTMTllVmJJVmc4dVU1NFg2SHAxa0tNamlPZ3FhaC03ei1HQnJWcl82R1F4UU5mMVVXSlNLd2VuM043SUxYWGJLVFRqbjNpdk5jUlE?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-20T08:00:00+00:00", "published_display": "20 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics (KLRS) Stock Forecast and Price Target 2026 $KLRS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9QNFNDb2RRNHlIR3hub3RMdExHU2tXZU9BT2lfOVFpc3ZKMkxhbWpMeGNobDJhbGFrZ0JzZndnZktXRWVrTlhuaVNQb3lLUnlZTVlvd3I3QmVmamoxazhTUURqQnkwUQ?oc=5", "source_name": "MarketBeat", "published_at": "2025-05-26T17:21:05+00:00", "published_display": "26 May 2025 17:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics (KLRS) Stock Price, News & Analysis $KLRS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1tazN1VDNqX0dPNFRTbnkyck9rOFUwTFFQWG81a2VMQVBxNm94eDBjYzNNeEFOVi01endfTGRpMElla1ZPU2tHYlhZcWw0bUpWNmJYdFZDbGtZZw?oc=5", "source_name": "MarketBeat", "published_at": "2025-05-25T04:45:32+00:00", "published_display": "25 May 2025 04:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for Kalaris Therapeutics Inc. (KLRS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE5TUWJYQmlvaEstMkNabEVJLXFGQnljNEJWS3NIZ0NUdVYxNVFHR0lIZU1PVEd3bWpLQm9EN2J5dVc1NlQ5MlFnMFVqbnNlcUhlcEJ3VEl0a3NuTVhVdUdhWW9NR054dlp0ZmRLQ09fODMxMDgtLW4zOA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-03-20T18:32:11+00:00", "published_display": "20 Mar 2025 18:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KLRS Stock Price and Chart \u2014 NASDAQ:KLRS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5UaUhZaG5RbGF0bVN5N21YSVJtOTk3bU1iTHJBbjRLY21oOFdoN3NYdHlOYjloSm0teG9qdTlHOER4S0dYZE10Vmt6QjZrMHFFYUU3X3RVSEtzRTd4?oc=5", "source_name": "TradingView", "published_at": "2025-03-19T16:33:20+00:00", "published_display": "19 Mar 2025 16:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris to go public via reverse merger with AlloVir", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQY2RSNno3RlNFSmxib0JOTldNZmFyYkRSNkMzT0ZjYmFWRGxMdnRkV0VfdE9xZWRuOWdMaklQRktJSWxVemZEODZyblMxUDhLckQyNm9VS1oyM1FkR0pncHJuZmRIbmVkbUlGZUpya3l3V3pXTjN3RG5aU3g4N0Jvc3o1UEJxWnlMYWUxVmlSdmg1aEk?oc=5", "source_name": "BioPharma Dive", "published_at": "2024-11-08T08:00:00+00:00", "published_display": "08 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOS3k3T0xVbmRhUVMzWXVZYi1EZFlTeVVoV1R6WDVjcG83ZFZnUHRad3htZVpKUmNCVVVqaG4zV01ZUE5TbmVDZ2RyNHFZOEF0OUhUU0xTSmsySVB2RDJTQWNJZ1hNVUE2UkozR0NxVzNCbVl4WTFwZzRteHFFU2RmSjJORVA5OUhBS3VfdFdUU2ZOMmZFU0RPWUMxOHA1VnJLRFdMVQ?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:58+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics (KLRS) Edges Higher as Stock Tests Key Resistance Near $5.12 - Wave Extension", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPNm1mNml1Wm5zQnVic3pMcnNWVjdjUmV3VzlnN1U0MTZIeGlUTDhBSlo1d0FYQkdJd1NKRThFZWQ2TVB2T1BxNnpQc1lGWDlBUjBiU2Y2RGVGa0hpd0tYcmw2VHkxZGp2bkRfUDRIQUluTk1hWkNUcVZ4SzVOWkliMlgzVDJ3cmI0VGRuMlhQbXlDNk1Pa1c5QjM2Yk5YTXd6YV9vdkhJZzRzWHNaMnRzQ1IyMTFVZlM4OWZR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-08T13:43:25+00:00", "published_display": "08 Jul 2026 13:43", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics appoints Laurie Keating to board By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPR2J0LU5pYXMxTFVxbVQ4c0ZJOHRTM0dpamxCa0lSQXRuTWxPTlpVX1VDTThhUU5OOTJnT0EwMmdxQnBhblFjb1N6SUx6b0w3OXNWRTdUSm1KaFJRTjdYUkJjY2NfSzZEOXkxUE9oazFoLUM2aGJNc2t2MG5xZUt5UWdtenRKUUVnaFZmWURUVU4xV2Rza3NPc3hvQVE4bHB1YWFhQURfSy1LM0RFWXVXM3M1Yms?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-06T21:15:25+00:00", "published_display": "06 Jul 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics Announces Board and Audit Committee Changes", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNRzBidW1SakxXQXVBTFhhVEI1US1qd0t5WE9vZHNkZmJqTEhzQWFfbDJMaHR1eFdjQTE3YmNzYnJVM2J0T3pXV3dyWWNhZDV5TVhQSzNBSVA2TFlmRUsxUHRWbmVkNHY3cVFYSWFKc244dDU3bmdhcW80eXkzSnJnNXVpVDFWSW9wQnZfb3pIcVlKQl9TSTUtak5CeENEX0U3TW8zS3A4dUNCWjJuZ0x5WXlZVUdLRUU?oc=5", "source_name": "TipRanks", "published_at": "2026-07-06T20:35:52+00:00", "published_display": "06 Jul 2026 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Appoints Laurie Keating to Board of Directors", "summary": "Kalaris Therapeutics has announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. Keating, a highly experienced biotechnology executive, will bring extensive strategic, operational, and legal expertise to the board, aiding Kalaris in its ne", "url": "https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/kalaris-appoints-laurie-keating-to-board-of-directors/2379340", "source_name": "The Manila Times", "published_at": "2026-07-06T20:40:08", "published_display": "06 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Kalaris Appoints Laurie Keating to Board of Directors", "summary": "The provided content is a placeholder document. Without access to the actual content, a summary cannot be generated. It is expected to be a press release announcing the appointment of Laurie Keating to the Board of Directors of Kalaris.", "url": "https://www.moomoo.com/news/post/72538507/press-release-kalaris-appoints-laurie-keating-to-board-of-directors?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-06T19:43:10", "published_display": "06 Jul 2026 19:43", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Kalaris Therapeutics, Inc. \u2013 NASDAQ:KLRS", "summary": "The article displays the \"Price to book forward\" for Kalaris Therapeutics, Inc. (NASDAQ: KLRS) on TradingView. It provides basic information about the company including its stock market listing and offers links to various financial data, news, and community features on the platfo", "url": "https://www.tradingview.com/symbols/NASDAQ-KLRS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:09:25", "published_display": "30 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Kalaris Therapeutics, Inc. \u2013 NASDAQ:KLRS", "summary": "This article mentions the enterprise value to EBITDA forward for Kalaris Therapeutics, Inc., traded on NASDAQ under the symbol KLRS. It appears to be a stub or a section from a financial data platform, providing a heading for a specific financial metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-KLRS/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T11:41:36", "published_display": "29 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling", "summary": "Kalaris Therapeutics, Inc. announced the upcoming presentation of Phase 1a clinical data for TH103 at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. The presentation will detail the first-in-human evaluation of TH103, a dual-targeting VEGF/HSPG biologic fo", "url": "https://www.manilatimes.net/2026/06/23/tmt-newswire/globenewswire/kalaris-announces-upcoming-presentation-of-th103-phase-1a-clinical-data-at-american-society-of-retina-specialists-ph-1b2-clinical-trial-actively-enrolling/2370862", "source_name": "The Manila Times", "published_at": "2026-06-26T17:10:34", "published_display": "26 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics, Inc. Actuals & Estimates (NASDAQ:KLRS)", "summary": "This article provides an overview of Kalaris Therapeutics, Inc. (NASDAQ:KLRS) stock performance, financial data, and analyst forecasts. It details the current stock price, historical highs and lows, market capitalization, earnings per share, and revenue, alongside analyst price t", "url": "https://www.tradingview.com/symbols/NASDAQ-KLRS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:10:10", "published_display": "26 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KLRS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast and analysis for Kalaris Therapeutics, Inc. (KLRS) stock, including analyst price targets, historical stock performance, and financial data. It covers current stock price, volatility, market capitalization, and upcoming earnings reports, ", "url": "https://www.tradingview.com/symbols/NASDAQ-KLRS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:40:11", "published_display": "25 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris to present Phase 1a data on retinal drug at ASRS meeting By Investing.com", "summary": "Kalaris Therapeutics (NASDAQ:KLRS) announced it will present Phase 1a data for its investigational drug TH103, a dual-targeting biologic for neovascular age-related macular degeneration, at the American Society of Retina Specialists 2026 Annual Meeting. The company also stated th", "url": "https://m.in.investing.com/news/stock-market-news/kalaris-to-present-phase-1a-data-on-retinal-drug-at-asrs-meeting-93CH-5466613?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-06-24T01:10:18", "published_display": "24 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris to present Phase 1a data on retinal drug at ASRS meeting", "summary": "Kalaris Therapeutics (NASDAQ:KLRS) announced it will present Phase 1a data for its investigational drug TH103, a dual-targeting biologic for neovascular age-related macular degeneration, at the American Society of Retina Specialists 2026 Annual Meeting on July 17, 2026. The compa", "url": "https://ng.investing.com/news/stock-market-news/kalaris-to-present-phase-1a-data-on-retinal-drug-at-asrs-meeting-93CH-2570104", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T23:10:27", "published_display": "23 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics (Nasdaq:KLRS) - Stock Analysis", "summary": "Kalaris Therapeutics (KLRS) is a clinical-stage biopharmaceutical company focused on treatments for retinal diseases. The company is currently unprofitable and has seen dilution of shares, but its lead asset, TH103, has shown positive Phase 1a data for neovascular Age-Related Mac", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-klrs/kalaris-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-21T23:40:11", "published_display": "21 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics Inc (KLRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Kalaris Therapeutics Inc (KLRS), focusing on business segments, regional revenue, and profit contribution. It notes that relevant data for these categories for FY2019, FY2020, and FY2021 have not yet been disclosed by the company. The", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-klrs/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T15:09:53", "published_display": "19 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics Inc (KLRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Kalaris Therapeutics Inc (KLRS), detailing its price momentum, support and resistance levels, and insights from various technical indicators and moving averages. The stock currently trades between a resistance of $5.54 and support of ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-klrs/technical", "source_name": "TradingKey", "published_at": "2026-06-18T21:09:47", "published_display": "18 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics Inc (KLRS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Kalaris Therapeutics Inc (KLRS). It indicates that the company has not distributed any dividends in the past five years but has a significant 23-to-1 merger-related stock split scheduled for January 10, 202", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-klrs/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:01", "published_display": "18 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics Inc (KLRS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Kalaris Therapeutics Inc (KLRS) has an earnings forecast score of 8.75, ranking high in the Biotechnology & Medical Research industry. Analysts have set an average price target of $20.00, with varying highs and lows, and largely recommend a \"Buy\" for the stock. The company's prev", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-klrs/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:01", "published_display": "17 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics Climbs 7.8% as Biotech Momentum Builds (KLRS) - Wave Extension", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPM1p2am05cHhSV1kycV9GeXFHN2JVRDdlUWhxUG1iT19Xbjcxcm80aFAyelE5RWkwYlFjNm1pVEExWk1ZcVJBb2ZDTkRGaVVfOGZPaTRabHhaUmJZR090azZNR1pEVnNpZnFHcXNvSWE0dHA1bWhYWTJ0aWZiQnJVbU1VZFloZW1sbnhSbDdIemFRRlNKeWpWLTI5N1hDaVc0QTVzZE15UQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris to Present at Clinical Trials at the Summit 2026", "summary": "Kalaris Therapeutics, Inc. announced it will present Phase 1a clinical data for its lead asset, TH103, at Clinical Trials at the Summit (CTS) 2026. The presentation will feature single ascending dose results from treatment-na\u00efve patients with Neovascular Age-Related Macular Degen", "url": "https://www.manilatimes.net/2026/06/12/tmt-newswire/globenewswire/kalaris-to-present-at-clinical-trials-at-the-summit-2026/2364390", "source_name": "The Manila Times", "published_at": "2026-06-17T02:09:25", "published_display": "17 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen initiates Kalaris stock coverage with buy rating", "summary": "TD Cowen initiated coverage on Kalaris Therapeutics Inc. (NASDAQ:KLRS) with a buy rating, highlighting its differentiated anti-VEGF treatment TH103 and a potential $15 billion market opportunity. Analysts have set price targets ranging from $7 to $25. Despite a previous trial pau", "url": "https://m.uk.investing.com/news/stock-market-news/td-cowen-initiates-kalaris-stock-coverage-with-buy-rating-93CH-4727617?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-15T19:40:45", "published_display": "15 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KLRS Initiates Coverage On by TD Cowen -- Rating Set to Buy", "summary": "TD Cowen has initiated coverage on Kalaris Therapeutics (KLRS) with a Buy rating, noting the company's focus on developing therapeutics for retinal diseases. Despite a low GF Score\u2122 of 14/100 indicating potential profitability challenges, the company has a strong financial streng", "url": "https://www.gurufocus.com/news/8916771/klrs-initiates-coverage-on-by-td-cowen-rating-set-to-buy", "source_name": "GuruFocus", "published_at": "2026-06-15T18:37:40", "published_display": "15 Jun 2026 18:37", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Initiates Kalaris Therapeutics at Buy", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/td-cowen-initiates-kalaris-therapeutics-100528337.html", "source_name": "MT Newswires", "published_at": "2026-06-15T10:05:28+00:00", "published_display": "15 Jun 2026 10:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First-in-human TH103 eye trial data to be presented at Las Vegas summit", "summary": "Kalaris Therapeutics (Nasdaq: KLRS) will present Phase 1a clinical data for its lead asset, TH103, at Clinical Trials at the Summit (CTS) 2026 in Las Vegas. The presentation will detail single ascending dose results from treatment-na\u00efve patients with neovascular age-related macul", "url": "https://www.stocktitan.net/news/KLRS/kalaris-to-present-at-clinical-trials-at-the-summit-087ko6zxj3zq.html", "source_name": "Stock Titan", "published_at": "2026-06-13T07:10:08", "published_display": "13 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KLRS SEC Filings - Kalaris Therapeutics Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for investors to access Kalaris Therapeutics Inc. (KLRS) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, and 8-K material event disclosures. Recent filings cover the re-election of directors, ratification of auditor", "url": "https://www.stocktitan.net/sec-filings/KLRS/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:10:19", "published_display": "12 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOSnJXLW05bjhaNFNtZTExWmptRkktcGxIblZVenpyekpQYXo5Rm9mdlNYNjZScUZ3ZjBYNmFDY2tzMXVrUnlIVU1EcEpFY04zSGNuNU9tQlVvTDNNaDdHMHhzYjRNMFpFRENPeXVaUEZuTDkzNFRsVU9QWWpPalZZRFNiM2MwY2FMV25TUHRoUDFfa3BqajlibVl0a1NLWGJINHpN?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics (KLRS) director receives 9,000-stock option grant", "summary": "Kalaris Therapeutics director Srinivas Akkaraju was granted options to buy 9,000 shares of common stock on June 3, 2026, with an exercise price of $4.72 per share. These options will vest in full on the earlier of June 3, 2027, or the company\u2019s 2027 Annual Meeting of Stockholders", "url": "https://www.stocktitan.net/sec-filings/KLRS/form-4-kalaris-therapeutics-inc-insider-trading-activity-e1a07873e8aa.html", "source_name": "Stock Titan", "published_at": "2026-06-05T04:09:54", "published_display": "05 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics (KLRS) director awarded 9,000 stock options", "summary": "Kalaris Therapeutics director Anthony P. Adamis has been granted 9,000 stock options with an exercise price of $4.72 per share and an expiration date of June 2, 2036. These options are scheduled to vest fully by June 3, 2027, or the company's 2027 annual meeting, contingent on hi", "url": "https://www.stocktitan.net/sec-filings/KLRS/form-4-kalaris-therapeutics-inc-insider-trading-activity-da746940ddc6.html", "source_name": "Stock Titan", "published_at": "2026-06-05T03:38:47", "published_display": "05 Jun 2026 03:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics (KLRS) holders elect board, choose annual say-on-pay", "summary": "Kalaris Therapeutics, Inc. (KLRS) announced the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. Shareholders elected three directors, Napoleone Ferrara, David Hallal, and Leone Patterson, with strong support. Furthermore, they approved the advisory vote o", "url": "https://www.stocktitan.net/sec-filings/KLRS/8-k-kalaris-therapeutics-inc-reports-material-event-3bd83e236c1e.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:08:56", "published_display": "04 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Kalaris Therapeutics, Inc. Insider Trading Activity", "summary": "Kalaris Therapeutics, Inc. director Michael Dybbs was granted 9,000 stock options, with an exercise price of $4.72 per share and an expiration date of June 2, 2036. These options are scheduled to vest fully by June 3, 2027, or the date of the company's 2027 Annual Meeting of Stoc", "url": "https://www.stocktitan.net/sec-filings/KLRS/form-4-kalaris-therapeutics-inc-insider-trading-activity-3efdd24553f3.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:08:56", "published_display": "04 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics (KLRS) director receives stock options for 9,000 shares", "summary": "Kalaris Therapeutics director David Hallal was granted stock options for 9,000 shares of common stock with an exercise price of $4.72 per share. The options, granted on June 3, 2026, vest in full on the earlier of June 3, 2027, or the company's 2027 annual stockholder meeting, co", "url": "https://www.stocktitan.net/sec-filings/KLRS/form-4-kalaris-therapeutics-inc-insider-trading-activity-f85d3e3ed18a.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:08:56", "published_display": "04 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kaskela Law LLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. Shareholders and Encourages Investors With Losses to Contact The Firm - KLRS", "summary": "Kaskela Law LLC has initiated an investigation into potential legal claims for shareholders of Kalaris Therapeutics, Inc. (NASDAQ:KLRS). This follows a significant decline in Kalaris' stock price, dropping nearly 45% to under $5.00 per share since its merger with AlloVir, Inc. in", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/kaskela-law-llc-announces-investigation-on-behalf-of-kalaris-the-1173256", "source_name": "ACCESS Newswire", "published_at": "2026-06-04T07:59:00", "published_display": "04 Jun 2026 07:59", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock Higher - Estimate Revision Count", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQRnVSaGxtYzljQmFQclRVU3NZeTYxRGhUOVp1RkU5ekdxN0dndlNjS0lrd2toTlBJZWNYQV9WdGFyeUNvc0h4ZmRfTkpwQ3VwVDVjS2hvWjZpZHk5UDIwOHMwaEZkLXoyczUtUnVFb3U1LW84QWxrTjVoX24weWZQU0Nmdmp2SzFrNHcxYVRLT09xemV2MHlqSzhxdlJ4UXJRdHk3d2Rsb1hPM1N3c2s0VnRSSDkteUhkSU5oc2F0RlFaUU9pMXktNG93?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre-Revenue Biotech - Quarterly Profit Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPc093dmtGV2lXb0JIS0RKSzNqY0hXZXFYSHZSdVFGM3RHRjZMY3QyYnZhSjh2UFpkUktyR0wtY1J6TTV3a1otWnBEOWhhd3hpSUNlQ09UenBtMGx3bktYTGVXM05fU3dtbTVyaHpnaWU4OWxpeVNreFBtTHlEaVVHVHR4VlJiTjE1TzQ2SnZieGVCMU5zNnlXX1A1WXZPdUlKNXk0czlDZ3pxSkg0SWJSdS03UURxMTN5S2dUems2UWdram80Y09tTG5jT0l5TGdQSjlKT25LMzNQclhxc2UwbmJYTUFhUQ?oc=5", "source_name": "M\u011bsto B\u0159eclav", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics director Akkaraju\u2019s fund buys $1.18m stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOUDdqM21RYml1MkNmZEp5Rl8wWVl6NUZ0MEJHdkQtQWl1T3ViLWVBNlExbkNNbmdDdWJhejROTC1ULTdxWXVDemRxUm5UZGNpUVI5MmU3RURuVi1CcmpaOGhJUzY5RXc5VGRtUFNsV1BucFc5alg2cXRlQ2tha2I5S0l0RFFaNG9BSi1mUjhYaElJYmVERFk1bzl0bzZaVlhvMzlFT1A4THN4N3BqN0VURWJacEpGSFNsVmFrZGVLZ011bWc?oc=5", "source_name": "Investing.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Initiates Kalaris Therapeutics at Outperform With $17 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-initiates-kalaris-therapeutics-outperform-114847081.html", "source_name": "MT Newswires", "published_at": "2026-05-14T11:48:47+00:00", "published_display": "14 May 2026 11:48", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kalaris-reports-first-quarter-2026-120000027.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T12:00:00+00:00", "published_display": "12 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics (NASDAQ:KLRS) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-20T08:00:00+00:00", "published_display": "20 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics (KLRS) Stock Forecast and Price Target 2026 $KLRS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9QNFNDb2RRNHlIR3hub3RMdExHU2tXZU9BT2lfOVFpc3ZKMkxhbWpMeGNobDJhbGFrZ0JzZndnZktXRWVrTlhuaVNQb3lLUnlZTVlvd3I3QmVmamoxazhTUURqQnkwUQ?oc=5", "source_name": "MarketBeat", "published_at": "2025-05-26T17:21:05+00:00", "published_display": "26 May 2025 17:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris Therapeutics (KLRS) Stock Price, News & Analysis $KLRS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1tazN1VDNqX0dPNFRTbnkyck9rOFUwTFFQWG81a2VMQVBxNm94eDBjYzNNeEFOVi01endfTGRpMElla1ZPU2tHYlhZcWw0bUpWNmJYdFZDbGtZZw?oc=5", "source_name": "MarketBeat", "published_at": "2025-05-25T04:45:32+00:00", "published_display": "25 May 2025 04:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for Kalaris Therapeutics Inc. (KLRS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE5TUWJYQmlvaEstMkNabEVJLXFGQnljNEJWS3NIZ0NUdVYxNVFHR0lIZU1PVEd3bWpLQm9EN2J5dVc1NlQ5MlFnMFVqbnNlcUhlcEJ3VEl0a3NuTVhVdUdhWW9NR054dlp0ZmRLQ09fODMxMDgtLW4zOA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-03-20T18:32:11+00:00", "published_display": "20 Mar 2025 18:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KLRS Stock Price and Chart \u2014 NASDAQ:KLRS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5UaUhZaG5RbGF0bVN5N21YSVJtOTk3bU1iTHJBbjRLY21oOFdoN3NYdHlOYjloSm0teG9qdTlHOER4S0dYZE10Vmt6QjZrMHFFYUU3X3RVSEtzRTd4?oc=5", "source_name": "TradingView", "published_at": "2025-03-19T16:33:20+00:00", "published_display": "19 Mar 2025 16:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kalaris to go public via reverse merger with AlloVir", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQY2RSNno3RlNFSmxib0JOTldNZmFyYkRSNkMzT0ZjYmFWRGxMdnRkV0VfdE9xZWRuOWdMaklQRktJSWxVemZEODZyblMxUDhLckQyNm9VS1oyM1FkR0pncHJuZmRIbmVkbUlGZUpya3l3V3pXTjN3RG5aU3g4N0Jvc3o1UEJxWnlMYWUxVmlSdmg1aEk?oc=5", "source_name": "BioPharma Dive", "published_at": "2024-11-08T08:00:00+00:00", "published_display": "08 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 51, "sentiment_summary": {"positive": 18, "negative": 2, "neutral": 31, "score": 57, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 11.55, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 8.8, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.45, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}], "positive_events": 18, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 4.44, "latest_week": "2026-07-10", "one_week_move": -6.5, "four_week_move": 2.5, "twelve_week_move": -29.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.709434, "market_dynamics_buy_signal": false, "relative_strength": -36.649858, "fair_value_gap": -73.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 41.6987, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.5% over one week, +2.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "TradingKey", "count": 4}, {"label": "The Manila Times", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "dars.gov.et", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 5}, {"label": "Deals and strategy", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.5% over one week, +2.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board"}], "updated_at": "2026-07-16T08:05:14.996258+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}